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ABSTRACT: 
Significant growth of biopharmaceuticals requires powerful analytical methods to better 
understand their structure by establishing a complete characterization. To this end, a combination of 
bottom-up, middle-up and intact molecule levels with a capillary electrophoresis-mass spectrometry 
coupling has been performed to have a comprehensive picture of monoclonal antibodies. In this study, 
7 worldwide health authorities approved mAbs have been analyzed to get information about their 
charge heterogeneity, the identification of post translational modifications (PTMs), their location and 
relative quantitation. Intact mAbs isoforms have been partially separated in less than 12 minutes and 
enabled to have a global illustration of mAbs heterogeneity and high masses PTMs characterization 
notably major N-glycosylation forms. Particularly, 2X-glycosylated and 1X-glycosylated forms have 
been partially separated. To deepen characterize PTMs carried by the backbone structure, advanced 
investigations at a middle-up level have been performed. Limited IdeS proteolysis allowed to study 
independently Fc/2 and F(ab)’2 fragments. Following the same separation conditions, isoforms of 
these fragments have been separated and data interpretation allowed to disclose additional PTMs as 
K-clip, oxidations or deamidations.  A second intermediate level has been examined by adding a 
reduction step to establish a more precise assessment of PTMs and isoforms from the F(ab)’2 
fragment. This reduction step released the light chains from the Fd fragment to get only 25 kDa 
fragments to analyze. CE-ESI-MS coupling allowed to get more information particularly about low 
masses PTMs. The precise location and relative quantitation of each PTM has been investigated at the 
peptidic level induced by a tryptic digestion of the studied mAbs. The concordance of the results shows 
the efficiency of the CE-ESI-MS coupling to characterize mAbs and highlight the need of the multi-level 
combination to get a comprehensive characterization of biotherapeutics. 
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1. Introduction 
Over the last decades, the expanding development of monoclonal antibodies (mAbs) has led 
to numerous solutions employed in therapeutic treatment. These glycoproteins become one of the 
main class of biopharmaceuticals involved in various treatment such as cancers, auto-immune disease 
but also to prevent transplant rejection [1, 2]. Nowadays, more than 70 mAbs have been approved by 
worldwide health authorities and commercially available and 80 candidates are in the last phase of 
clinical trials [3]. The increasing number of candidates is supported by the expanding range of biological 
targets identified and high specificity of mAbs to the corresponding antigens. MAbs production 
processes are based on cell lines inducing their own modifications that irremediably elicits a diversity 
of isoforms. The mixture of proteoforms involved by the variety of macro and micro-heterogeneities 
leads to a charge heterogeneity. It can be explained by post-translational modifications (PTMs) such 
as N-glycosylations, partial amino-acid sequence cleavage, deamidations or oxidations which can occur 
during fabrication, purification, conditioning or storage steps. Combining certain of these PTMs may 
result in a difference of biological activity of the treatment or affect the stability and safety of the 
drugs.  
Currently, a large panel of analytical techniques are required to perform an advanced 
characterization of mAbs among biotherapeutics [4]. Mass spectrometry (MS) is now recognized as a 
major tool in protein structural characterization [5] and requested for example in ICH Q6B guideline 
(https://www.ich.org/page/search-index-ich-guidelines). Recent advances in high resolution MS 
instrumentation and have even led to the use of MS-based methods for quality control testing in a 
current Good Manufacturing Practice environment [6, 7]. The continuous evolution of separative 
techniques and MS hyphenation enhances protein mixtures understanding and is widely applicable in 
mAbs assessments [8-10]. On-line capillary electrophoresis-mass spectrometry coupling via an 
electrospray ionization interface (CE-ESI-MS) has already proved its ability to separate and characterize 
micro-variants of mAbs [11-13]. The effectiveness of miniaturized systems oriented our strategy to CE-
ESI-MS to separate and characterize mAbs proteoforms and rank Critical Quality Attributes during early 
developability [14], forced degradation [15] and comparability studies [16]. It offers the possibility to 
combine protein separation and analysis at different levels such as bottom-up, middle-up and intact 
levels that justifies its use in biotherapeutic characterization[17, 18]. Indeed, the intrinsic 
heterogeneity of mAbs involves the need of a comprehensive characterization in order to obtain a 
model the most realistic of the real drug. 
 Traditional mAb characterization has been operated following a “bottom-up” strategy with a 
LC-MS/MS coupling or more recently with a sheathless CE-ESI-MS/MS coupling [9, 19]. Although the 
important ability to identify different proteoforms with minor micro-heterogeneities, this approach 
can occur some artifactual modifications due to sample preparation and chemical treatment. This 
limitation can be surpassed by a comprehensive structural characterization at higher levels as middle-
up and intact molecule approaches. These respectively intermediate and ultimate levels seem to be 
particularly interesting for biopharmaceutical companies because of their ability to illustrate the 
heterogeneity of produced mAbs. Middle-up level can be performed by digesting mAbs with IdeS 
protease which cleaves Immunoglobulins (IgGs) under the hinge region between 2 Glycine residues at 
a specific amino-acid sequence CPPCPAPELLG/GPSVF to obtain Fc/2 fragments (25 kDa) and F(ab)’2 
fragment (100 kDa). Optional reducing step can be done to reduce intra-chain and inter-chain disulfide 
bonds to cleave the F(ab)’2 fragment by releasing the light chain (LC) (25 kDa) from the Fd fragment 
(25 kDa), facilitating the mAb assessment. To complete mAbs characterization, an intact protein level 
corresponding to the highest analytical level of mAbs has been investigated. Based on the CE-ESI-MS 
development previously described by our group, a partial separation of intact mAbs has been 
performed and spectra interpretation highlighted a charge heterogeneity which may be explained by 
a combination of PTMs [20]. As expected, PTMs characterized at this upper level are essentially high 
weight major modifications as N-glycosylations but surprisingly it also disclosed some common low 
masses PTMs as oxidations or deamidations. 
In this work, we report the development of a multi-level combined approach implementing a 
complete structural characterization of mAbs based on a CE-ESI-MS coupling. Adalimumab (huIgG1, 
CHO), natalizumab (hzIgG4, NS0), nivolumab (huIgG4, CHO), palivizumab (hzIgG1, SP2/0), infliximab 
remicade® (chIgG1, SP2/0), rituximab (chIgG1, CHO) and trastuzumab (hzIgG1, CHO) were the seven 
commercial mAbs considered in this multi-level assessment. 
 
2. Experimental 
2.1. Chemicals 
Chemicals used were of analytical grade or high purity grade and purchased from Sigma-Aldrich 
(Saint Louis, MO, USA). Water used to prepare buffers and sample solutions was obtained using an 
ELGA purelab UHQ PS water purification system (Bucks, UK). Adalimumab, Natalizumab, Nivolumab, 
Palivizumab, Infliximab, Rituximab and Trastuzumab were obtained as European Union 
pharmaceutical-grade drug product from their respective manufacturers. 
 
2.2. Sample preparation 
2.2.1. Intact level 
For intact mAbs analysis, samples were desalted to remove all residual components of the storage 
solution. Samples were buffer exchanged with water three times at 4°C on Amicon centrifugal filters 
with a 10 kDa cut off (Merck, Darmstadt, Germany). Each centrifugation was made at 14’000 g speed 
during 20 min to claw back mAbs at 33.3 µM. Then, mAbs were led to a final concentration of 6.7 µM 
using formic acid 1% - methanol 30% (v/v). 
2.2.2. Middle-up level  
MAbs were clived under the hinge region with IdeS enzyme (FabRICATOR®, Genovis), to obtain two 
Fc/2 fragments and one f(ab)’2 fragment. Samples were diluted in 200 mM ammonium bicarbonate 
pH 6.5 to a final concentration of 1 g/L. A volume of 2.24 µL of IdeS (67 U/µL) was added to each sample 
and left at 37°C for 45 min. After digestion, three desalting steps were performed with water on 
Amicon centrifugal filters with a 10 kDa cut off at 4°C and 14’000 g for 20 min. Then, mAbs were led to 
a final concentration of 6.7 µM using formic acid 1% - methanol 30% (v/v). 
2.2.3. Middle-up reduced level 
After IdeS digestion, 20 mM TCEP was added to samples then left 30 minutes at room temperature to 
reduce disulfide bonds on F(ab)’2 fragments. The reduction of F(ab)’2 fragments results in the 
dissociation of the light chain (LC) and the Fd fragment. After reduction, three desalting steps were 
performed with water on Amicon centrifugal filters with a 10 kDa cut off at 4°C and 14’000 g for 20 
min. Then, mAbs were led to a final concentration of 6.7 µM using formic acid 1% - methanol 30% 
(v/v). 
2.2.3. Bottom-up level 
A volume corresponding to 100 μg (0.67 nmol) of protein was used. Samples were first diluted from 
stock solution to a concentration of 45.6 μM by using water. A second dilution to a concentration of 
22.2 μM was performed by using 0.1% RapiGest surfactant an incubation at 40°C for 10 min. Reduction 
of the samples was then achieved by the addition of dithiothreitol (DTT, final concentration of 25 mM) 
and incubation at 95°C for 5 min. To perform tryptic digestion, a volume of 1 μL of trypsin (0.5μg/μL) 
was added to the samples that were left at room temperature for 3h. Then another volume of 1μL was 
added afterward and digestion was performed overnight at 37°C. In order to cleave the surfactant, 
formic acid (FA) was added to the samples at a final concentration of 1% (v/v) and samples were left 
at room temperature (RT) for 2h. Samples were finally diluted to a final protein concentration of 2.2 
μM using ammonium acetate 200 mM (pH 4.0). 
 
2.3. Capillary Electrophoresis 
All of the CE experiments have been done on a CESI8000 capillary electrophoresis system from Sciex 
Separation (Brea, CA, USA) hyphenated to a timsTOF Pro (Bruker Daltonics, Bremen, Germany). For 
Intact and middle-up levels analysis, bare fused silica capillary (total length 100 cm; 30 µm i.d.) with 
porous tip on its end have been positively coated with polyethyleneimine (PEI) following Sciex 
protocols. A second capillary (total length 80 cm; 50 µm i.d.) allowed electric contact after a filling step 
of both with 3% acetic acid background electrolyte (BGE). Before each run, capillaries were flushed 3 
min at 50 psi with BGE. Samples were injected at 2 psi 10 seconds and separations were performed at 
-30 kV during 15 min. No capillary wash was done between each run in order to avoid any degradation 
of PEI coating. For tryptic digests, analyses have been performed on a bare fused silica capillary (total 
length 100 cm; 30 µm i.d.). BGE was acetic acid 10 % and 100 nL of 2.2 µM of mAbs have been injected 
in the capillary. Runs length was set at +20 kV during 60 min each.  
 
2.4 Mass spectrometry 
For each analysis level of mAbs, CE was hyphenated to a timsTOF Pro (Bruker daltonics, 
Bremen, Germany). This equipment is a hybrid mass spectrometer composed of an ion mobility cell, a 
quadrupole followed by a time-of-flight (TOF) analyzers. Contrary to bottom-up level, ion mobility cell 
was switch off for intact and intermediate analysis levels. Nano-ESI source parameters were set as 
follow: nanoESI voltage +1.5 kV while dry gas supplies was 1.2 L/min, source heating temperature 
150°C. Mass/charge (m/z) range was 1000 – 5000 in MS for intact mAbs analysis, 1000 – 4000 in MS 
for intermediate levels and 400 – 3000 for peptide level. Data processing was performed with 
DataAnalysis 5.1. Deconvolution of mass spectra was done using ESI Compass Maximum Entropy 
deconvolution option. All spectra were calibrated by external calibration using Peptide mix from 
Bruker. 
 
2.5. Data analysis 
MS data were analyzed with the dissect mode of DataAnalysis 5.1 software with an internal 
S/N threshold of 3 and a maximum of 10 overlapping compounds. Cut-off intensity of mass spectrum 
calculation was set at 0.1 %. After an automatic interpretation of the results, a manual validation has 
been performed on the results. MS spectra have been extracted from each peak represented on the 
base peak electropherogram. For intact mAbs analyses, each profile has been selected and 
deconvoluted between 140 and 160 kDa with the maximum entropy algorithm of DataAnalysis 5.1. to 
calculate the mass of corresponding compounds. Spectra obtained at the middle-up have been 
deconvoluted between 20 and 30 kDa for Fc/2, Fd and LC fragments and 90 to 100 kDa to identify 
f(ab)’2 fragment. Finally, fragments earned with reduction step added to the partial digestion with IdeS 
were sought only between 20 and 30 kDa. Manual and automatic results have been confronted to 
theoretical masses to detect any mass modification and get additional information about the 
characterized compounds. 
 
3. Results and discussion 
3.1. Intact level 
 Regarding capillary zone electrophoresis (CZE)-based methods for the characterization of 
mAbs charges variants, until 2016, almost all literature described quality control application in terms 
of product heterogeneity using CZE with UV detection [19, 21]. However, strategies with optical 
detection didn’t allow to obtain structural information for the basic and/or acidic variants representing 
the limitation of these methodologies. These last years, some reports revealed the usefulness of CZE-
MS for the assessment of macro-heterogeneity [13, 20, 22]. MS resolving power coupled CZE efficiency 
exhibited as well the baseline separation of 2X-glycosylated, 1X-glycosylated and aglycosylated 
population as the characterization of various other PTMs such as deamidation, oxidation or lysine 
clipped forms. In each cases, CZE experimental conditions are based on the use of a neutral or positive 
coated capillaries to avoid protein adsorption on the inner surface of the capillary wall. Indeed, due to 
the negative charge surface of the silanol groups, electrostatic interactions imply peak tailing 
phenomena degrading separation efficiency. Different strategies as positive polyethylenimine (PEI) or 
uncharged polyacrylamide coatings have been investigated [20, 22]. In a previous study, our group 
detailed a CZE-MS methodology to perform the analysis of mAbs at the intact level. Based on the use 
of a PEI coated capillary, acidic background electrolyte (BGE) and acidic methanol/water sample buffer, 
micro-variant separations of intact mAbs have been observed in less than 20 minutes (RSD < 3% on 
migration times (n=10)).  In the present study and in order to assess the methodology, this CZE-MS 
method has been applied to seven world-wide health authorities approved mAbs. Separation obtained 
(Fig. 1), showed differences of profile depending on the nature of the mAbs. This expected result can 
be explained by the difference of heterogeneity of each mAbs added to the difference of pI values 
(from 7.1 to 9.1 [23]). However, a general profile can be observe with the main peak surrounded by 
acidic variants before and basic variants after. This order of separation is explained by the use of 
positive coated capillary which confers a reverse electroosmotic mode. MS data processing consisted 
to integrate and deconvolute each peak of the based peak electropherogram. Results of identified 
isoforms for the seven mAbs are given in the Table S1 of the supporting information. As a first PTMs 
characterization step about cyclisation of glutamine (Glu) or glutamic acid (E), seven mAbs have to be 
compared in two groups. Indeed, three analyzed mAbs (adalimumab, infliximab, trastuzumab) own N-
terminal Glu residue while four others (nivolumab, palivizumab, natalizumab, rituximab) own N-
terminal Gln. Concerning the Glu residue’s group, no cyclisation has been observed while 100% of 2X-
pyroGln have been identified for the Gln residue’s group. These results mean that either the mAbs are 
not modified or MS sensitivity is not sufficient to detect small amounts of modified mAbs. Only the 
analysis at a lower level of complexity can answer this question. Concerning the other PTMs, 
adalimumab will be select as a representative example to illustrate these obtained MS results (Fig. 2). 
For each peak, deconvoluted mass spectra exhibited a glycoform pattern corresponding to 2X-
glycosylated and 1X-glycosylated forms. Focused on the 2X-glycosylation populations, measured 
average masses (Table 1) corresponding to G0F/G0F, G0F/G1F and G0F/G0F-GlcNac while G0F and G1F 
are identified for the 1X-glycosyled forms. As expected, no separation of mAbs isoforms has been 
observed whereas separation obtained between 2X-glycosyled and 1X-glycosylated forms [20, 22]. 
Concerning possible acidic or basic variants, mass difference between 3 and 15 Da were observed. As 
already described in the literature, the most important antibody basic charge variants are iso-Asp 
modification, C-terminal Lys truncation, aglycosylation, incomplete cyclization of the N-terminal Gln to 
pyroGln or methionine oxidation; whereas sialylation, asparagine deamidation, glycation, 
cysteinylation are the most commonly observed acidic variants [24]. Primary structure of adalimumab 
carries several residues (Asp, Asn, Met…) which can be potentially isomerized, deamidated or oxidized. 
However, due to the mass accuracy limitation of the mass spectrometer, it is impossible to conclude 
without any ambiguity on the exact modification. Only hypothesis can be formulated on the real nature 
of acidic and basic variant. To alleviate this limitation, only a multi-level analysis involving partial 
enzymatic digestion could be an alternative solution to ensure the identification and deeper 
characterize mAbs isoforms. 
3.2. Middle-up level 
An increasingly number of reports from worldwide drug agencies such as the FDA and the EMA 
highlight the importance of multi-level characterization of mAbs [25-27]. Middle-up analysis of mAbs 
involving IdeS partial digestion has been performed to get additional information and confirm results 
earned with the intact protein strategy. This intermediate level consists in cleaving the 
immunoglobulin (IgG) specifically under the hinge region to obtain F(ab)’2 and Fc/2 fragments. The 
two fragments are respectively around 100 kDa and 25 kDa. Method development has been carried 
out to separate and analyze fragments with such a mass variance. CZE conditions have not been subject 
to modification between each level of analysis. After mAb infusion, the mass range has been fixed 
between 1000 and 4000 Thomson to incorporate the charge envelope of the two kinds of fragments. 
Separations have been performed in less than 11 minutes for each mAbs (Fig. 1) (RSD < 3% on migration 
times (n=3)). In each case, 4 to 6 peaks have been separated, with 2 to 5 Fc/2 isoforms and 1 to 4 
F(ab)’2 isoforms (Table S1). After a comparison between theoretical masses and experimental ones, 
major glycoforms as Man5, GlcNac, G0F, G1F and G2F already found at the intact molecule level are 
also recovered. Supplementary glycoforms are linked with Fc/2 fragments of the different mAbs. For 
example, G0 glycoform has been found on each mAb except natalizumab, G1 and G2 forms have been 
identified on respectively 5 and 3 mAbs including natalizumab, nivolumab and trastuzumab (Table S1). 
In addition, each mAb spectra deconvolution highlighted the presence of lower mass PTMs well 
defined such as K-clip which is a loss of the terminal lysine on the HC, methionine oxidation but also 
potential asparagine deamidation. Concerning the Glu/PyroGlu and Gln/PyroGln groups of mAbs 
described in the intact level section, similar results have been observed at the middle-up level, namely, 
100% N-terminal Glu and 100% PyroGln respectively.  
As at the intact level analysis, adalimumab was chosen to illustrate these results. 
Electropherogram in Fig. 3 shows a separation of the IdeS digest of adalimumab with several peaks, 
reflecting a separation of F(ab)’2 and Fc/2 fragments. Deconvoluted spectra revealed a baseline 
separation of F(ab)’2 and Fc/2 fragments and a partial separation of Fc/2 isoforms (Table 2) . Results 
showed Fc/2 fragment with G0F-GlcNac, Man5, Man6, G0F, G1F and G2F glycoforms. These 
observation are in agreement with the main glycloforms observed at the intact level. Moreover, 
additional glycosylation has been obviously characterized due to the difference of weight between 
Fc/2 fragment (25 kDa) and intact mAbs (150 kDa). Another PTMs such as K-clip on C-term of Fc/2, 
correlated to a difference of mass of 128 Da, have been observed in a large number of glycoform. As 
at the upper level, low mass differences were detected on Fc/2 and F(ab)’2 fragments corresponding 
to acidic or basic variants. Regarding the Fc/2 fragments, difference of 1 Da corresponding to one 
deamidation of Asn have been observed in the majority of the identified glycoforms. Concerning 
F(ab)’2, difference between 4 to 8 Da have been observed which can correspond to several 
deamidation. However, despite the compatibility of results between theoretical and experimental 
data, same limitation of the mass accuracy of mass spectrometer can be underline for 100 kDa 
fragments. Even if there is sufficient Asn residues in F(ab)’2 fragment to obtain several deamidation, 
only hypothesis can be formulated on the real nature of the modification. A possibility to overcome 
this limitation is to reduce F(ab)’2 fragment. Indeed, reduction of disulfide bonds anchored in F(ab)’2 
fragment could release the LC from the Fd part of the mAb and thus allow a deeper structural 
investigation. 
 
3.3. Reduced middle-up level 
Reduction workflow consisted to break the disulfide bonds with the reducing agent tris(2-
carboxyethyl)phosphine (TCEP) to release the light chain LC from the Fd part. Hence, the masses of the 
three fragments earned with this sample treatment were all about 25 kDa and enabled a more 
comprehensive analysis of the F(ab)’2 fragment. MS analytical parameters have been optimized to 
redefine the m/z range and key factors such as the accumulation time of ions in the mass spectrometer 
but also the pre-pulse storage time in order to enhance both detection and mass accuracy. As expected 
at this lower level, for each mAbs, 3 to 7 peaks have been observed on the electropherogram in less 
than 10 minutes, thus proving the efficiency and fastness of the separation method (Fig. 1). For each 
mAb, the quantity of peaks drawn by the total ion electropherogram is increasing and respective peaks’ 
efficacy are better, more intense and better resolved than results at the upper levels.  
Besides the presence of the three theoretical fragments, information has been obtained by 
deconvoluted spectra regarding the nature of PTMs found on the mAbs, such as low mass differences 
and oxidations. As shown at higher analytical levels, spectra interpretation of Fd fragments revealed 
pyroGln in Fd N-terminal position for mAbs bearing a Gln on N-term HC, and Glu in the same position 
for mAbs bearing a Glu on N-term HC. In addition, oxidation and deamidation have been clearly located 
on LC or Fd fragments, completing the characterization of PTMs at the different level. On a global basis 
of the seven mAbs, in respect of Fc/2 fragments, besides previously identified glycoforms, additional 
ones have been partially separated but unambiguously characterized such as Man5, Man6, G0F-GlcNac 
as indexed in Table S1 with or without K-clip. Moreover, uncomplete glycosylation forms have been 
detected and separated, extending the characterization of PTMs on mAbs.  
Using the example of adalimumab results illustrated in Fig. 4, numerous peaks are drawn on 
the total ion electropherogram (TIE) arising from a separation of LC, Fd and Fc/2 fragments. Some 
glycosylation forms like G1F, G0 or G1 already found at intact and middle-up levels are also recovered 
at this level. Low masses PTMs as asparagine deamidation and methionine oxidation are also found at 
this level, enhancing the interpretation of MS spectra and more widely mAbs characterization (Table 
3). This secondary intermediate level led to new limitations concerning the identification of PTMs on 
the 3 formed fragments. Indeed, all three Fd, Fc/2 and LC fragments earned by an Ides digestion added 
with a reduction step have a molecular weight about 25 kDa. Hence, major peaks on MS spectra may 
interfere with some minor peaks representing fragments carrying PTMs with a lower intensity. More 
precisely, conglomeration of many species differing slightly on their mass can be co-eluted. Ions 
detection is clearly dependent from ionization, transfer and detection so hidden peaks can sometimes 
reveal some strong present PTMs. Moreover, even if fragments have a reduced mass allowing a better 
characterization, they can possess numbers of different possible site of modification as Asn, Asp or 
Met for example. At this level of characterization and without fragmentation process, it is impossible 
to locate precisely the modification. At the moment, the bottom-up level remains the better 
alternative totally complementary with higher levels. This third mAb analytical level enables to get 
precise structural information on peptides. The protein backbone slicing with an enzymatic tool allows 
to isolate the PTMs and opens a way to characterize and relatively quantify their presence. 
 
3.4. Bottom-up level 
One of the reference method to determine protein amino acid sequence and to locate or 
quantify PTMs is the MS based bottom-up analysis. For primary structure characterization, this 
methodology is particularly crucial in early development of therapeutic antibodies as well as during 
long-term life cycle management of the biopharmaceutical products. This level 3 of mAb analysis allows 
to perform their characterization with respect to several aspects that define their primary structure, 
including amino acid sequence, glycosylation and other types of PTMs such as oxidation of Met, 
deamidation of Asn, cyclisation of Gln/Glu an isomerization of Asp [28].  
Based on previous work [29], mAbs samples were treated by an in solution tryptic digestion. 
Peptides earned had a length between two and about sixty amino acids. For each mAbs, tryptic peptide 
mixtures were separated using the sheathless CZE-ESI-MS/MS system based on their charge state in 
solution as well as their hydrodynamic radius. Peptides were identified from MS/MS spectra in an 
approach similar that used in bottom-up proteomic experiments.  
For each mAbs, sequence coverage of 100% of both the heavy chain and light chain was obtained 
from a single injection of 200 fmol (Fig. S2). Regarding MS/MS spectra, remarkable number of y and b 
ions allows peptide identification in peptide fragment fingerprinting strategy. Identification of more 
than 80% of the y and b ions composing the seven different mAbs are systematically obtained.  
Concerning N-glycosylation characterization, using the same set of CZE-ESI-MS/MS data, 14 of 
the main Fc N-Glycan species typically found in therapeutic IgG mAbs produced in CHO, NS0 and SP2/0 
cell lines were systematically identified. Peak assignment of glyco-structures was performed based on 
accurate mass measurement in MS1, provided by high resolution MS (mass accuracy below 2 ppm) 
and MS/MS spectra, respectively. As the intact and middle-up analysis, results of adalimumab have 
been selected to illustrate the CZE-ESI-MS method performance (Fig. 5), however, results on the other 
six mAbs are done in the supporting information Fig. S2). The glycan profiling of Adalimumab (Fig. 5a) 
has been designed using the evaluation of the relative occurrence levels of each glycopeptide. 
Reproducibility of the method has been already described in the literature by our group [30]. Briefly, 
triplicates of mAbs digestion were performed using different experimenters and triplicates injections 
of each digested samples were carried out. Calculated values of standard deviation never exceeding 
4% were observed, and a systematic comparison of the glycosylation patterns obtained for each mAbs 
was compared with the HILIC-FD reference method. This validated CZE-ESI-MS/MS method as a 
powerful approach to perform relative quantitation of N-glycan species for mAb characterization. 
Moreover, N-glycan species identified at this bottom-up level are in accordance with those forms 
characterized at intact and intermediate levels. G0F, G1F, G2F, G0, G1, G2, Man5, Man6, G0F-GlcNac 
are Figured out at all levels but the bottom-up level allows to get the precise localization and relatively 
quantify them. Besides glycosylation, other PTMs must also be considered following potential 
influence in the affinity between a mAb and its corresponding antigen. Same protocol has been 
processed for the identification and the relative quantification of selected PTMs such as methionine 
oxidation, N-terminal glutamic acid cyclization, asparagine deamidation and isomerization of aspartic 
acid. Data showed in Fig. 5b for adalimumab (supporting information Fig. S2 for the six other mAbs) 
that every single PTM monitored could be successfully characterized and relatively quantified. 
Advantages of bottom-up as compared to intact of middle-up approaches, is the faculty to locate 
precisely the modification on the backbone of the mAbs using MS/MS spectra. Moreover, the ability 
of CE to separate in each case the intact peptide to the modified peptide allowed to calculate the 
abundance level of the modification. It is interesting to note that for the 3 mAbs with N-terminal Glu 
in the HC, low abundance level of cyclisation is observed (<4%) while for the 4 mAbs with N-terminal 
Gln in the HC, peptide is almost totally modified (<90%). The presence or not of amino acid cyclization 
is in accordance with the other analytical levels however only bottom-up level has sufficient sensitivity 
to detect small amount of modified peptide. Concerning oxidation of methionine, focusing on DTLMISR 
peptide, which is common to every analyzed mAbs, less than 5% modified peptide was observed in 
each case. However, depending of the mAbs, other oxidized methionine could be characterized 
elsewhere on the protein backbone with relative abundance until 10%. This kind of occasional 
modification has also been found at the middle-up level, reinforcing the quality and robustness of the 
methods employed at the 3 levels. Finally, all deamidation of asparagine and isomerization of 
isoaspartic acid have been identified and characterized. Except for one peptide in rituximab bearing a 
D/isoD modification (abundance level of the modified peptide >20%), calculated abundance level is 
included between 0 to 12%. Just as the previous results, the bottom-up strategy corroborate the 
information gathered at the intact and middle-up levels, where identical masses proteins were 
separated, nonetheless.   
The consistency of the cross checked-results of combined intact, intermediate and bottom-up 
levels demonstrate the power and robustness of the CZE-ESI-MS to fully characterize therapeutics. 
Highest levels could be used first to have a global illustration of the charge heterogeneity but also to 
get a qualitative information about the different N-glycosylations and PTMs attendance. Lower levels 
and particularly the third level (bottom-up) should be preferred to get quantitative information and 
precise localization of the PTMs and to ensure the amino acid structure. 
 
4. Conclusion 
In this work, seven commercial mAbs have been thoroughly characterized by a sheathless CZE-
ESI-MS coupling. MAbs are glycoproteins which can be analyzed at three complementary analytical 
levels known as intact level, middle-up level and bottom-up level.  Based on a previous work from our 
group to separate intact mAbs isoforms, supplemental levels have been investigated to get a deeper 
characterization and detect additional information such as PTMs combination and location. Contrary 
to the bottom-up analysis performed on a bare fused silica capillary, a PEI positive coating has been 
set up to avoid protein adsorption on the inner surface of the capillary at intact and middle-up levels. 
These upper levels analyses have been surveyed to get structural information as realistically as possible 
by avoiding artifactual modifications due to heavy sample preparation. A partial separation of intact 
isoforms has been obtained in less than 12 minutes. MS spectra interpretation of intact mAbs exposed 
the presence of major high molecular weight PTMs as N-glycosylations. Intermediate level has been 
investigated using an IdeS digestion to facilitate the characterization of low mass PTMs on mAbs. The 
separation of F(ab)’2 and Fc/2 fragments induced by the cleavage (respectively of 100 kDa and 25 kDa) 
has been performed following the same separation conditions used at the intact level. In each case, 
isoforms separation has been obtained in less than 11 minutes and disclosed a separation between 
F(ab)’2 and Fc/2 fragments. More precisely, isoforms of Fc/2 fragments have been elucidated carrying 
different N-glycosylations and other PTMs as methionine oxidations or K-clips. Mass accuracy enabled 
to get supplemental N-glycans structure. However, the F(ab)’2 fragments were still too imposing to 
undoubtedly assign very low mass PTMs such as asparagine deamidation. The solution employed in 
this study was to add a reducing step to release LC from Fd part by breaking up interchain disulfide 
bonds. All fragments induced by this workflow are about 25 kDa each. The separation has been 
performed in less than 10 minutes and gave numerous peaks in each case, corresponding to various 
isoforms of fragments. Here, high accuracy provided by the CE-ESI-MS coupling enabled the 
assessment of macro and micro-heterogeneities from N-glycosylations to asparagine deamidation. 
Nevertheless, the precise location of PTMs could only provide from a peptidic level assessment. The 
bottom-up level has been examined to identify, locate and relatively quantify all kind of PTMs. The 
synergy of PTMs identified at this lower level and the upper levels underline the paramount 
importance of the combination of multi-level analyses to establish a comprehensive characterization 
of mAbs and get an illustration as close as possible to the real protein mix administered to patients. 
However, the multi-level characterization of mAbs presented in this work could be qualified as a first 
step to integrate the quality control process of biotherapeutics. An exhaustive quality control of 
biomolecules could not be reached without the complete validation of CE-ESI-MS methods and the 
comparison of obtained results with orthogonal techniques. 
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Captions 
 
Fig. 1 CZE-ESI-MS separation of intact, middle-up and reduced middle-up of the seven mAbs 
 Fig.2 CZE-ESI-MS separation of intact adalimumab and corresponding deconvoluted mass spectra.  
 
 Fig.3 CZE-ESI-MS separation of IdeS digest of adalimumab and corresponding deconvoluted mass 
spectra.  
 Fig. 4 CZE-ESI-MS separation of reduced IdeS digest of adalimumab and corresponding deconvoluted 
mass spectra.  
 
Fig. 5 Glycoform semiquantitative analysis (A) and other PTMs occurrence levels (B) for adalimumab 
obtained by CE-ESI-MS.  
 
 
 
 
 
 
Table 1: Assignment of species observed for intact Adalimumab after CZE-ESI-MS analysis 
Fragment glycan species 
observed 
mass (Da) 
theoretical 
mass (Da) 
assigned PTM 
migration 
time (min) 
Δ mass 
(Da) 
  G0F 146619 146635   10.55 16 
 G1F 146781 146797  10.55 16 
 G0F/G0F-GlcNac 147861 147877  10.45 16 
 G0F/G0F-GlcNac 147867 147876  10.15 9 
 G0F/G0F-GlcNac 147869 147877  10.05 8 
 G0F/G0F-GlcNac 147871 147877  9.95 6 
 G0F/G0F 148064 148080  10.45 16 
 G0F/G0F 148070 148080  10.15 10 
 G0F/G0F 148071 148080  10.05 9 
 G0F/G0F 148075 148080  9.95 5 
 G0F/G1F 148227 148242  10.45 15 
 G0F/G1F 148232 148242  10.15 10 
  G0F/G1F 148232 148242   10.05 10 
  G0F/G1F 148236 148242   9.95 6 
Annotation: see supporting information Figure S1 
Table 2: Assignment of species observed for IdeS digest of Adalimumab after CZE-ESI-MS analysis 
fragment glycan species 
observed 
mass (Da) 
theoretical 
mass (Da) 
assigned PTM 
migration 
time (min) 
Δ mass 
(Da) 
Fc/2 non-glycosylated 23754.0 23754.6 Kclip 10.00 0.6 
Fc/2 [H1N2F1] 24467.8 24468.3 Kclip + 1 deam * 9.55 0.5 
Fc/2 [H2N2F1] 24631.0 24631.4 Kclip 9.55 0.4 
Fc/2 [H2N3F1] 24833.6 24833.6 Kclip + 1 deam* 9.80 0.0 
Fc/2 G0F [H3N4F1] 25200.1 25199.9 Kclip 9.65 -0.2 
Fc/2 G0F [H3N4F1] 25328.1 25328.1 - 9.90 0.0 
Fc/2 G0F [H3N4F1] 25327.1 25327.1 deam* 10.30 0.0 
Fc/2 G1F [H4N4F1] 25361.0 25361.1 Kclip + 1 deam* 9.80 0.1 
Fc/2 G1F [H4N4F1] 25361.6 25362.1 Kclip 10.30 0.5 
Fc/2 G1F [H4N4F1] 25490.1 25490.2 - 10.00 0.1 
Fc/2 G2F [H5N4F1] 25524.3 25524.2 Kclip 9.55 -0.1 
Fc/2 G0F-GlcNac [H3N3F1] 24995.7 24995.8 Kclip + 1 deam* 9.65 0.1 
Fc/2 G0F-GlcNac [H3N3F1] 24996.3 24996.7 Kclip 10.30 0.5 
Fc/2 G0F-GlcNac [H3N3F1] 25125.3 25124.9 - 10.00 -0.7 
Fc/2 G0 [H3N4] 25052.6 25052.8 Kclip + 1 deam* 9.55 0.2 
Fc/2 Man5 [H5N2] 24971.7 24971.7 Kclip 9.55 0.0 
Fc/2 Man6 [H6N2] 25132.0 25132.8 Kclip + 1 deam * 9.55 0.8 
f(ab)'2 - 97713 97712 4 deam * 10.00 1 
f(ab)'2 - 97711 97711 5 deam * 10.30 0 
f(ab)'2 - 97708 97708 8 deam * 10.70 0 
Annotation: see supporting information Figure S1 
 
  
Table 3: Assignment of species observed for reduced IdeS digest of Adalimumab 
 
fragment glycan species 
observed 
mass (Da) 
theoretical 
mass (Da) 
assigned PTM 
migration 
time (min) 
Δ mass 
(Da) 
Fc/2 G0F [H3N4F1] 25201.9 25202.0 Kclip + 2 deam * 8.90 0.1 
Fc/2 G0F [H3N4F1] 25199.7 25200.0 Kclip + 4 deam * 9.25 0.3 
Fc/2 G1F [H4N4F1] 25362.8 25363.2 Kclip + 3 deam * 9.05 0.4 
Fc/2 G1F-GlcNac [H4N3F1] 25157.9 25157.9 Kclip + 1 deam * 9.25 0.0 
Fc/2 G1 [H4N4] 25217.7 25218.0 Kclip + 2 deam * 9.25 0.3 
LC - 23409.7 23409.9 2 deam * 8.80 0.2 
LC - 23406.2 23406.0 6 deam * 9.35 -0.2 
Fd - 25456.2 25456.4 2 deam * 8.45 0.2 
Fd - 25454.3 25454.4 4 deam * 9.50 0.1 
Fd - 25472.3 25472.4 oxy + 2 deam * 8.45 0.1 
Annotation: see supporting information Figure S1 
 
 
